Lyra Therapeutics/$LYRA
Lyra Therapeutics shares are trading higher after reporting positive Phase 3 trial results for LYR-210 in treating chronic rhinosinusitis.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyra Therapeutics
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Ticker
$LYRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
30
ISIN
US55234L2043
Website
LYRA Metrics
BasicAdvanced
$27M
-
-$60.66
0.01
-
Price and volume
Market cap
$27M
Beta
0.01
52-week high
$37.50
52-week low
$3.81
Financial strength
Current ratio
2.956
Quick ratio
2.767
Long term debt to equity
751.885
Total debt to equity
861.467
Management effectiveness
Return on assets (TTM)
-28.54%
Return on equity (TTM)
-195.46%
Valuation
Price to revenue (TTM)
22.403
Price to book
6.89
Price to tangible book (TTM)
6.89
Price to free cash flow (TTM)
-0.469
Growth
Revenue change (TTM)
-29.46%
Earnings per share change (TTM)
-0.30%
3-year revenue growth (CAGR)
16.32%
3-year earnings per share growth (CAGR)
-30.81%
LYRA News
AllArticlesVideos
This penny stock just spiked 550% in a day; Time to buy?
Finbold·1 day ago
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewsWire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyra Therapeutics stock?
Lyra Therapeutics (LYRA) has a market cap of $27M as of June 03, 2025.
What is the P/E ratio for Lyra Therapeutics stock?
The price to earnings (P/E) ratio for Lyra Therapeutics (LYRA) stock is 0 as of June 03, 2025.
Does Lyra Therapeutics stock pay dividends?
No, Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders as of June 03, 2025.
When is the next Lyra Therapeutics dividend payment date?
Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyra Therapeutics?
Lyra Therapeutics (LYRA) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.